Clinical Trial Update: A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety, efficacy, and pharmacokinetics of Miricorilant (CORT118335) in obese adults with schizophrenia or bipolar disorder treated with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Antipsychotic-induced Weight Gain
• Bipolar Disorder
• Schizophrenia

Drugs mentioned

• Miricorilant (CORT118335)

Snippet

Sponsor: Corcept Therapeutics | Conditions: Antipsychotic-induced Weight Gain (AIWG) | Phase 2 | Status: COMPLETED | Results posted: 2024-09-19